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Abstract 
In this work, the microwave radiation is adopted for remote activation of pharmaceutical drug capsules inside the human 
body in order to release drugs at a pre-determined time and location. An array of controllable transmitting sources is used 
to produce a constructive interference at a certain focus point inside the body, where the drugs are then released from the 
specially designed capsules. An experimental setup for microwave activation has been developed and tested on a body 




In the year 2008, 48% of the people in the United States took at least one prescription drug in a single month. The 
prescription drug use had increased by 4% compared to 1998 [1]. With current increasing intake of drugs, a more 
efficient and controllable way of delivering the drugs is of great interest. 
 
Oral delivery of pharmaceuticals is the preferred method compared to intravenous injection because of lower costs, 
reduced risks associated with the injection, and higher patient compliance due to self-administration. However the 
traditional oral delivery faces several challenges such as low drug permeability (not to be confused with electromagnetic 
permeability) through the gastrointestinal epithelium [2,3] and degradation of the active pharmaceutical components in 
the stomach [4]. 
 
Inherently the problem with current drug delivery systems, e.g. in the form of pills is the limited external control of when 
the drug is dissolved and absorbed by the body. Typically, the drug release is controlled by the intestinal pH gradient and 
is therefore released over a large segment of the intestine. The drugs are coated with special protective coatings which 
dissolve at a certain pH value. The time and the location for the drug release is therefore difficult to control. For certain 
diseases such as schizophrenia and diabetes, dosing must be stable and reliable [5]. 
 
Pharmaceutical drugs taken orally are normally designed to release the drug in the small intestine because there, the 
drugs typically exhibit maximal absorption [6]. The small intestines are less than 3 cm in diameter [7, pp. 272]. 
 
A number of techniques have been developed to externally control the drug delivery. These include, but are not limited 
to, the use of ultrasound [8], light waves [9], magnetic fields [10] and radio waves below 100 MHz [11]. Complex 
systems have also been integrated into a drug delivery module consisting of a receiving inductor, control circuitry chip 
and a drug delivery chip [12]. Each of these methods has its pros and cons. 
 
The alternative method that described in this work is to focus microwave energy inside the human body to get localized 
high-amplitude fields. These are then used to activate the specially designed micro-containers. 
 
2. Microwave Activation of Drug Release  
The purpose of the described here microwave activation system 
is to provide a method of releasing drugs inside the body, 
unobtrusively, i.e. without disturbing a patient. The concept is 
illustrated in Figure 1, where one of the anticipated scenarios is 
shown. A person is lying on a bed, sleeping after having ingested 
numerous capsules that contain pharmaceutical drugs. At a 
certain time, and at a pre-determined location inside the human 
body, the microwave activation system focuses electromagnetic 
energy that opens the capsules and releases the medical drug. 
 
Obviously, the essence of the external activation of 
pharmaceutical drugs with microwaves depends on the ability to 
induce electromagnetic power at certain areas inside the body. A 
documented side effect of being irradiated by electromagnetic 
waves is that unwanted heating of areas, other than intended, can 
occur. A method for reducing the side effects is, to superimpose 
electromagnetic waves from multiple sources, creating a focus 
point. 
 
Figure 1. Remote activation of drug release 
using electromagnetic radiation. 
Tx Tx 
Tx Tx 
There are a number of critical design-choices to be made in a system that is to radiate electromagnetic waves inside the 
human body. These include operating frequency, number and location of transmitting antennas, pulsed vs. continuous 
wave operation, power level and flexibility of the system. 
 
Generally with increasing frequency, attenuation in biological tissues increases and makes it more challenging to 
penetrate deeper into the body. Higher frequency signals, due to smaller wavelength, are able to focus onto smaller areas. 
Components, such as antennas, can be made smaller and that impacts the overall size of the system. Considering these 
tradeoffs, the operating frequency of the experimental setup described in this work has been chosen in ISM band and is 
approximately 2.45 GHz. 
 
In Figure 2, a schematic drawing of the implemented setup is presented. A human torso phantom is in the center of the 
setup. To simplify the setup only four transmitters were implemented. They are evenly distributed around the phantom as 
it is shown in the Figure. Focusing of the electromagnetic 
energy is achieved by choosing the amplitude and phase of the 
transmitted signal. Microwave absorbers are placed in the 
plane of measurement, where one is placed behind each 
receiver and one between each receiver as shown in the 
Figure. 
 
The submerged in the phantom sleeve dipole antenna (red dot 
in Figure 2) is mounted on the lid of the phantom and used as 
a probe for measuring the field distribution inside the 
phantom. The lid can be rotated 360 deg in a continuous 
movement. The submerged antenna can also be moved 
continuously back and forth, from the centre of the phantom.  
 
In the conducted experiments a number of arbitrary focusing 
points were pre-determined in order to examine the focusing 
abilities of the microwave activation system. The experimental 
data showed clear focusing points at the pre-determined 
locations for points less than 4 cm from the centre of the 
phantom, i.e. deep inside the lossy phantom. In those cases, 
the focus point is the highest amplitude-point across a 
diameter larger than 3.6 cm. For comparison, the small 
intestine in humans are typically less than 3 cm in diameter [7, 
pp. 272] and is the place where the drug release is meant to take place. High-amplitude areas and spots (hot spots) 
appeared also at other locations than at the focusing point as was expected. This is a persistent problem in non-invasive 
hyperthermia systems as well. Increase of transmitting antennas should reduce the number of high-amplitude areas 
outside the focus area. A more detailed description and analysis of the achieved experimental results will be given at the 
conference presentation. 
 
3. Drug Capsule 
The inherent high losses of biological tissues at microwave frequencies make it challenging to penetrate deep into tissues 
with sufficient power levels. It is therefore required to have a very sensitive receiving structure on the drug capsule to 
absorb a significant part of the available power in order to use that energy to open the capsule. The anticipated scenario is 
illustrated in Figure 3 (a). A highly resonant structure, the split-ring resonator, is introduced on a lid of the capsule which 
contains a medicine. A resonator is able to induce locally high intensity fields at the resonance frequency, compared to 
other frequencies (refer to Figure 3. (b) and (c)) [13]. 
 
At the resonance frequency of the SRRs on the drug capsule structure, a relatively strong  electric field is generated in the 
gaps of the rings and in the separation between them. The alternating field induces currents in the lossy dielectric lid 
where part of the electric currents are converted into heat, due to power loss (Figure 2(c)). This causes an increase of the 
temperature in the lid and by that, opens the capsule and releases the pharmaceutical drug. Practically, this can be 
accomplished by having the lid constructed of a polymer, which can abruptly change its adhesion, viscosity or 
permeability (a measure of the ability of a porous material to allow fluids to pass through it) when heated by just a few 
degrees. A layer of adhesive material, with a melting point several degrees above the ambient temperature, placed 
between the lid and the capsule could also operate as a release mechanism for the pharmaceutical drug. 
 
      
Figure 2. Schematic representation of the 
experimental setup. 
 
Figure 3. Illustration of the activation (opening) process. (a) - Split-ring resonators on a lid on top of a capsule and a drug 
being released. (b) and (c) - Temperature distribution of the capsule as a result of a power loss in the lid. (b) represents 
the temperature distribution at 2.3 GHz and (c) at 2.43 GHz. Notice the difference in temperature. 
 
The analysis in [13] shows the existence of an optimal complex permittivity of the lid material which results in the 
highest temperature rise. 
 
4. Summary 
In this work, a method of remotely activating and releasing pharmaceutical drugs inside the human body with the use of 
microwaves was investigated. Current limitations in external control of the specific location and the time of a drug 
release inside the human body formed the motivation for this study. The microwave activation system was developed on 
the basis of being an unobtrusive system, i.e. without disturbing the prospective patients. Four external antennas were 
designed to irradiate the torso phantom along with four microwave transmitters. 
 
The measurement results revealed the wave behavior in the cylindrical phantom and the challenges of the focusing 
process. Even though focusing in the central part of the body can be achieved using the present setup, surface waves 
excited on the body-air interface disturbed the focusing of electromagnetic energy further away from the center of the 
body. 
 
It was also found that by optimizing the complex permittivity of the capsule lid, one can maximize temperature increase 
in the lid. The temperature increase can then be used to melt the lid and release the drugs. 
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